{"schema_version":"1","generated_at":"2026-10-29T17:45:42.827Z","data_as_of":"2026-10-23","url":"https://www.findmykol.com/kol/javier-pinilla-ibarz","json_url":"https://www.findmykol.com/kol/javier-pinilla-ibarz/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"javier-pinilla-ibarz","name":"Javier Pinilla-Ibarz","credential":"MD","title":"Senior Member, Moffitt Cancer Center","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Leukemia","therapeutic_areas":["Leukemia","Lymphoma"],"institution":"Moffitt Cancer Center","institution_url":"https://www.findmykol.com/institution/moffitt-cancer-center","city":"Tampa","state":"FL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1487736856","orcid":"0000-0003-3170-9648","openalex":"A5101811382"},"summary":"Javier Pinilla-Ibarz is Senior Member, Moffitt Cancer Center at Moffitt Cancer Center. OpenAlex indexes 483 publications with 13,371 citations (h-index 55).","overview":{"text":"Javier Pinilla-Ibarz, MD, is Senior Member, Moffitt Cancer Center. The public record shows 483 publications with 13,371 citations (h-index 55), centered on Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments. It also documents industry payments reported by 35 companies.","bullets":["Most recent indexed publication: 2026 · Case reports in pathology","Top research focus: Chronic Lymphocytic Leukemia Research","Open Payments reporting from 35 companies"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":0,"topics":3,"strength":3},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":0,"topics":1,"strength":1}],"research_topics":["Chronic Lymphocytic Leukemia Research","Lymphoma Diagnosis and Treatment","Chronic Myeloid Leukemia Treatments","T-cell and B-cell Immunology","Acute Myeloid Leukemia Research"],"drugs_studied":{"total":12,"shown":3,"withheld":9,"rows":[{"name":"Calquence","generic":"Acalabrutinib","trials":0,"payments":176,"publications":1,"mentions":177},{"name":"Brukinsa","generic":"Zanubrutinib","trials":0,"payments":85,"publications":1,"mentions":86},{"name":"Venclexta","generic":"Venetoclax","trials":0,"payments":84,"publications":2,"mentions":86}]},"works_with":{"total":30,"shown":3,"withheld":27,"rows":[{"name":"AstraZeneca Pharmaceuticals LP","trials":0,"payments":184,"mentions":184},{"name":"Abbvie Inc.","trials":0,"payments":75,"mentions":75},{"name":"Lilly USA, LLC","trials":0,"payments":73,"mentions":73}]}},"scholarship":{"works_count":483,"cited_by_count":13371,"h_index":55,"i10_index":163,"pubmed_count":6,"latest_activity_year":2026,"source":"works"},"trials":{"count":0,"shown":0,"withheld":0,"rows":[],"source":"trials"},"payments":{"company_count":35,"program_years":{"first":2021,"last":2025},"rows_total":78,"shown":3,"withheld":75,"rows":[{"payer":"Lilly USA, LLC","program_year":2025,"amount_usd":60972.27,"payment_count":32,"source_url":"https://openpaymentsdata.cms.gov/search?query=1487736856"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":44070.31,"payment_count":25,"source_url":"https://openpaymentsdata.cms.gov/search?query=1487736856"},{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":25212.8,"payment_count":21,"source_url":"https://openpaymentsdata.cms.gov/search?query=1487736856"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1487736856","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":92,"classes_total":2,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":82.3,"drugs":[{"name":"Calquence","share_pct":24.4},{"name":"Imbruvica","share_pct":22},{"name":"Brukinsa","share_pct":17.6},{"name":"Imatinib Mesylate","share_pct":13.2},{"name":"Bosulif","share_pct":7.8},{"name":"Jaypirca","share_pct":7.8},{"name":"Sprycel","share_pct":7.3}],"max_beneficiaries":null},{"class":"BCL-2 Inhibitor","setting":"prescribed","share_pct":9.6,"drugs":[{"name":"Venclexta","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":8,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":8,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"congress":{"count":96,"years":{"first":2008,"last":2025},"societies":["AACR","ASCO","ASH"],"shown":3,"withheld":93,"rows":[{"title":"Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States","society":"ASH","meeting":"ASH Annual Meeting","year":2025,"role":"presenting_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2025-2762","source_url":"https://doi.org/10.1182/blood-2025-2762","status":"verified"},{"title":"Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies","society":"ASH","meeting":"ASH Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2025-3531","source_url":"https://doi.org/10.1182/blood-2025-3531","status":"verified"},{"title":"Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study","society":"ASH","meeting":"ASH Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2025-3892","source_url":"https://doi.org/10.1182/blood-2025-3892","status":"verified"}],"source":"congress"},"publications":{"total":6,"shown":5,"withheld":1,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Plasmablastic Richter Transformation of Chronic Lymphocytic Leukemia With Aberrant Epithelial Marker Expression Presenting as a Pleural Effusion: A Diagnostic Challenge.","year":2026,"journal":"Case reports in pathology","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42824952/","status":"verified"},{"title":"Successful Zanubrutinib Monotherapy in a Rare CNS Presentation of Relapsed CLL.","year":2026,"journal":"Case reports in hematology","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41502491/","status":"verified"},{"title":"Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.","year":2025,"journal":"Hematology (Amsterdam, Netherlands)","types":["Journal Article","Consensus Statement"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41054963/","status":"verified"},{"title":"Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.","year":2024,"journal":"Blood cancer discovery","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/38194367/","status":"verified"},{"title":"History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience.","year":2023,"journal":"Journal of cancer research and clinical oncology","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/35962814/","status":"verified"}],"most_cited":{"total":483,"shown":5,"withheld":478,"rows":[{"title":"A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias","year":2013,"cited_by_count":1142,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1306494"},{"title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","year":2019,"cited_by_count":876,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1815281"},{"title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","year":2021,"cited_by_count":673,"type":"article","source_url":"https://doi.org/10.1200/jco.21.01210"},{"title":"Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial","year":2018,"cited_by_count":592,"type":"article","source_url":"https://doi.org/10.1182/blood-2016-09-739086"},{"title":"The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance","year":2008,"cited_by_count":452,"type":"article","source_url":"https://doi.org/10.1038/ni.1673"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Julio C. Chávez","coauthored_works":93},{"name":"Bijal Dinesh Shah","coauthored_works":88},{"name":"Eduardo M. Sotomayor","coauthored_works":86}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/javier-pinilla-ibarz-md","status":"verified"}]},"mentions":{"total":1,"shown":1,"rows":[{"url":"https://www.moffitt.org/research-science/researchers/javier-pinilla/","platform":"other","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"PhD (listed alongside MD)","source_url":"https://www.onclive.com/view/highlights-in-mpns-cll-with-drs-prithviraj-bose-and-javier-pinilla-ibarz","status":"provisional","collected_at":"2026-10-28"}]},"roles":{"total":1,"shown":1,"rows":[{"value":"Head of Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center","source_url":"https://www.moffitt.org/research-science/researchers/javier-pinilla/","status":"verified","collected_at":"2026-10-28"}]},"awards":{"total":3,"shown":3,"rows":[{"value":"Moffitt Physician of the Year Award (2016-17)","source_url":"https://www.moffitt.org/link/b6db3ed9aec44be8a5f61affb9dc21b9.aspx","status":"verified","collected_at":"2026-10-28"},{"value":"ASCO Career Development Award (2007)","source_url":"https://www.moffitt.org/link/b6db3ed9aec44be8a5f61affb9dc21b9.aspx","status":"verified","collected_at":"2026-10-28"},{"value":"ASCO Young Investigator Award (2003)","source_url":"https://www.moffitt.org/link/b6db3ed9aec44be8a5f61affb9dc21b9.aspx","status":"verified","collected_at":"2026-10-28"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Professor, Department of Oncologic Sciences, College of Medicine, University of South Florida","source_url":"https://www.hmpglobalevents.com/faculty/llmcongress/3234","status":"provisional","collected_at":"2026-10-28"}]},"media":{"total":4,"shown":3,"rows":[{"value":"Vumedi video, \"Emerging Trends in the Treatment Landscape of CLL\" (January 2025)","source_url":"https://www.vumedi.com/video/emerging-trends-in-the-treatment-landscape-of-cll","status":"provisional","collected_at":"2026-10-28"},{"value":"OncLive video with Chandler Park on CLL from the 2024 ASH Annual Meeting (December 2024)","source_url":"https://onclive.com/view/highlights-in-mpns-cll-with-drs-prithviraj-bose-and-javier-pinilla-ibarz","status":"provisional","collected_at":"2026-10-28"},{"value":"Patient Empowerment Network / Leukemia & Lymphoma Society webinar, \"Fact or Fiction? CLL Treatment and Side Effects\" (2019)","source_url":"https://LLS.ORG/patient-education-webcasts/fact-or-fiction-cll-treatment-and-side-effects","status":"provisional","collected_at":"2026-10-28"}]}},"similar":[{"name":"Ignacio Wistuba","slug":"ignacio-wistuba","institution":"Moffitt Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ignacio-wistuba","json_url":"https://www.findmykol.com/kol/ignacio-wistuba/profile.json"},{"name":"Christine Chung","slug":"christine-chung","institution":"Moffitt Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/christine-chung","json_url":"https://www.findmykol.com/kol/christine-chung/profile.json"},{"name":"Jonathan Strosberg","slug":"jonathan-strosberg","institution":"Moffitt Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jonathan-strosberg","json_url":"https://www.findmykol.com/kol/jonathan-strosberg/profile.json"},{"name":"Nikhil Khushalani","slug":"nikhil-khushalani","institution":"Moffitt Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/nikhil-khushalani","json_url":"https://www.findmykol.com/kol/nikhil-khushalani/profile.json"},{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Jorge Cortes","slug":"jorge-cortes","institution":"University of Alabama at Birmingham (UAB)","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/jorge-cortes","json_url":"https://www.findmykol.com/kol/jorge-cortes/profile.json"},{"name":"Ayalew Tefferi","slug":"ayalew-tefferi","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/ayalew-tefferi","json_url":"https://www.findmykol.com/kol/ayalew-tefferi/profile.json"},{"name":"Charles Sawyers","slug":"charles-sawyers","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/charles-sawyers","json_url":"https://www.findmykol.com/kol/charles-sawyers/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":75,"congress":93,"publications":1,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-28"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-28"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}